This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
HomeSearch

Menu

Close

SerotypesSerotypesSerotype CoverageSerotype SelectionCase CoverageEfficacyEfficacyInvasive Pneumococcal DiseaseOtitis MediaClinical Trial Results

Clinical Trial
Results

Study DesignImmunogenicitySafety ProfileDosing & Recommendations

Dosing &
Recommendations

DosingAdherenceDisease BurdenDisease BurdenDisease BurdenDisparitiesAccess & SupportAccess &
SupportOrder Prevnar 20®Commercial health plansEventsMaterialsVideosGeneral Inquiries
Prescribing InformationPatient InformationIndications Patient Site
Key serotypes in Prevnar 20®Prevnar 20 provides the broadest serotype coverage of any pediatric PCV by helping to protect against 20 important serotypes, including 5 serotypes not available in any other pediatric PCV1-3​​The serotypes in Prevnar 20 were selected based on:
Significant burden of IPDSerotypes 3, 22F, 12F, 33F, 19A, 15B, 19F, and 10A together were responsible for a significant burden of IPD in children <5 years of age nationwide from 2015 to 2016.4*
Increased severityPrior to the launch of Prevnar 20, serotypes 19A, 7F, 22F, 3, 15B, and 33F were observed in a study of children ≤18 years of age to be associated with severe clinical manifestations such as meningitis.5†
Antibiotic resistanceSeveral serotypes, including Prevnar 20–unique serotypes 10A, 11A, 12F, and 15B, have been associated with IPD strains bearing antibiotic resistance genes. 19A and 22F were also found to have antibiotic-resistant characteristics.4,6‡
Scroll left to view table

Serotypes unique to Prevnar 20 as compared with PCV15

Serotypes also in Prevnar 20

Prevnar 20 helps protect against the 20 Streptococcus pneumoniae serotypes in the vaccine.1 
There are no studies that compare the efficacy of Prevnar 20 to a 15-valent PCV.Prevnar 20 helps protect against the 20 Streptococcus pneumoniae serotypes in the vaccine.1 There are no studies that compare the efficacy of Prevnar 20 to a 15-valent PCV.Prevnar 20 provides broad coverage against potential IPD cases1-3,7 See IPD case coverage rates LoadingReferencesSerotype Coverage Prevnar 20 is built on the effectiveness of Prevnar®§ vaccines1,2

Learn more about the proven efficacy in a clinical trial of Prevnar (Pneumococcal 7-valent Conjugate Vaccine [Diphtheria CRM197 Protein])1,2

 Explore the results LoadingCDC=Centers for Disease Control and Prevention; IPD=invasive pneumococcal disease; PCV=pneumococcal conjugate vaccine; PCV7=7-valent pneumococcal conjugate vaccine; PCV15=15-valent pneumococcal conjugate vaccine.
*Based on S. pneumoniae isolates identified nationwide through CDC’s Active Bacterial Core surveillance (ABCs) during 2015 to 2016. Isolates were serotyped using whole genome sequencing for 5212 of 5334 isolates, of which 305 were in children <5 years.4
†Pneumococcal meningitis cases identified from patients ≤18 years from the US Pediatric Multicenter Pneumococcal Surveillance Study Group database of 8 children’s hospitals between January 1, 2007, and December 31, 2013. Serotypes were determined by the capsular swelling method using commercially available antisera (Statens Serum Institut, Copenhagen, Denmark; Dako Inc, Carpinteria, California) for 166 isolates.5
‡Based on S. pneumoniae isolates identified nationwide through CDC’s Active Bacterial Core surveillance (ABCs) during 2005 to 2013. Isolates were serotyped and genotyped using whole genome sequencing for 699 of 801 isolates in children <5 years recovered during 2009, 2012, and 2013. Antibiotic susceptibility to both β-lactam and non–β-lactam antimicrobials was assessed per study protocol. The level of resistance varied between isolates of a given serotype.6
§Prevnar includes Prevnar, Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), and Prevnar 20. In the US, Prevnar (PCV7) was available from 2000 to 2010, and Prevnar 13 was available from 2010 to 2024. Prevnar 20 has been available since 2023.1,2References:Prevnar 20® (Pneumococcal 20-valent Conjugate Vaccine) Prescribing Information. Wyeth Pharmaceuticals LLC, 2023.Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) Prescribing Information. Wyeth Pharmaceuticals LLC, 2019.Vaxneuvance™ (Pneumococcal 15-valent Conjugate Vaccine) Prescribing Information. Merck Sharp & Dohme Corp, 2023.Beall B, Chochua S, Gertz RE Jr, et al. A population-based descriptive atlas of invasive pneumococcal strains recovered within the U.S. during 2015-2016. Front Microbiol. 2018;9:2670.Olarte L, Barson WJ, Barson RM, et al. Impact of the 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in US children. Clin Infect Dis. 2015;61(5):767-775.Metcalf BJ, Gertz RE Jr, Gladstone RA, et al; Active Bacterial Core surveillance team. Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in
the USA. Clin Microbiol Infect. 2016;22(1):60.e9-60.e29.Centers for Disease Control and Prevention. ABCs Bact Facts Interactive data dashboard. Streptococcus pneumoniae. May 22, 2024. Accessed April 12, 2025. https://www.cdc.gov/abcs/bact-facts/data-dashboard.html
Manufactured by Wyeth Pharmaceuticals LLC.
Marketed by Pfizer Inc.
PP-PNR-USA-2905 © 2025 Pfizer Inc.
All rights reserved. June 2025

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-PNR-USA-2905
You are now leaving PfizerPro
You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.
PP-MCL-USA-0367
INDICATIONS 
  • Prevnar 20® is a vaccine indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older
  • Prevnar 20® is a vaccine indicated for active immunization for the prevention of otitis media caused by S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F in individuals 6 weeks through 5 years of age
IMPORTANT SAFETY INFORMATION
  • Do not administer Prevnar 20® to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 20® or to diphtheria toxoid
  • Safety and immunogenicity data on Prevnar 20® are not available for individuals in immunocompromised groups, and vaccination should be considered on an individual basis. Based on experience with pneumococcal vaccines, individuals with altered immunocompetence may have reduced immune responses to Prevnar 20®
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant’s medical status and the potential benefits and risks
  • In individuals 2, 4, 6, and 12 through 15 months of age vaccinated with a 4-dose schedule, the most commonly reported solicited adverse reactions (>10%) were irritability, pain at the injection site, drowsiness, decreased appetite, injection site redness, injection site swelling, and fever
  • In individuals 15 months through 17 years of age vaccinated with a single dose, the most commonly reported solicited adverse reactions (>10%) were irritability, pain at the injection site, drowsiness, fatigue and muscle pain, decreased appetite, injection site swelling and redness, headache, and fever
Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). ​​Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please click for Prevnar 20® Full Prescribing Information.INDICATIONSIndications
  • Prevnar 20® is a vaccine indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older
  • Prevnar 20® is a vaccine indicated for active immunization for the prevention of otitis media caused by S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F in individuals 6 weeks through 5 years of age